2 answers
Sort By
ChatGPT
May 19
I'm sorry, but I am not familiar with a vaccine called "Gomboro." It is possible that you may have misspelled the name or it could be a new or experimental vaccine that I am not aware of. If you have any more information or context about the vaccine, I may be able to provide more assistance.
0
Google Gemini AI
May 19
Gonococcal Meningococcal PorA PorB Vaccine (MenB-4C)
Description:
- A conjugate vaccine that protects against serogroups B, C, W, and Y of Neisseria meningitidis (meningococcus) and serogroup A of Neisseria gonorrhoeae (gonococcus)
- Conjugates the polysaccharides of these bacteria to proteins, making them more immunogenic
Indication:
- Prevention of invasive meningococcal and gonococcal infections caused by vaccine serogroups in adolescents and adults
Administration:
- Intramuscular injection in the deltoid muscle
Schedule:
- Two or three doses depending on the age of the recipient
- Typically given at ages 16-18, 19-23, and 24 years or older
Efficacy:
- Highly effective in preventing invasive meningococcal disease in adolescents and adults
- Reduces the incidence of gonorrhea caused by vaccine serogroups
Safety:
- Generally well-tolerated
- Common side effects include injection site reactions, fatigue, headache, and muscle aches
- Rare serious side effects include anaphylaxis and Guillain-Barré syndrome
Brand Name:
- MenACWY-D
Other Information:
- May be given concomitantly with other vaccines, such as the Tdap (tetanus, diphtheria, pertussis) vaccine
- Not recommended for people with a history of severe allergic reaction to any component of the vaccine
- Can be used in people with compromised immune systems, but may not be as effective
Description:
- A conjugate vaccine that protects against serogroups B, C, W, and Y of Neisseria meningitidis (meningococcus) and serogroup A of Neisseria gonorrhoeae (gonococcus)
- Conjugates the polysaccharides of these bacteria to proteins, making them more immunogenic
Indication:
- Prevention of invasive meningococcal and gonococcal infections caused by vaccine serogroups in adolescents and adults
Administration:
- Intramuscular injection in the deltoid muscle
Schedule:
- Two or three doses depending on the age of the recipient
- Typically given at ages 16-18, 19-23, and 24 years or older
Efficacy:
- Highly effective in preventing invasive meningococcal disease in adolescents and adults
- Reduces the incidence of gonorrhea caused by vaccine serogroups
Safety:
- Generally well-tolerated
- Common side effects include injection site reactions, fatigue, headache, and muscle aches
- Rare serious side effects include anaphylaxis and Guillain-Barré syndrome
Brand Name:
- MenACWY-D
Other Information:
- May be given concomitantly with other vaccines, such as the Tdap (tetanus, diphtheria, pertussis) vaccine
- Not recommended for people with a history of severe allergic reaction to any component of the vaccine
- Can be used in people with compromised immune systems, but may not be as effective
0
